Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC357526 | PMC |
| http://dx.doi.org/10.1128/jb.69.3.280-283.1955 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chrysomycins, Anti-Tuberculosis C-Glycoside Polyketides from sp. MS751.
Mar Drugs
June 2024
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
A new dimeric C-glycoside polyketide chrysomycin F (), along with four new monomeric compounds, chrysomycins G (), H (), I (), J (), as well as three known analogues, chrysomycins A (), B (), and C (), were isolated and characterised from a strain of sp. obtained from a sediment sample collected from the South China Sea. Their structures were determined by detailed spectroscopic analysis.
View Article and Find Full Text PDFOptimization of fermentation conditions and medium components for chrysomycin a production by Streptomyces sp. 891-B6.
BMC Microbiol
April 2024
School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China.
Background: Chrysomycin A (CA) is a promising antibiotic for treatment of Gram-positive bacterial infections and cancers. In order to enhance CA yield, optimization of fermentation conditions and medium components was carried out on strain Streptomyces sp. 891-B6, an UV-induced mutant with improved CA titer compared with its wide-type marine strain 891.
View Article and Find Full Text PDFOverexpression of a membrane transport system MSMEG_1381 and MSMEG_1382 confers multidrug resistance in Mycobacterium smegmatis.
Microb Pathog
December 2023
Mycobacterium Research Laboratory, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India. Electronic address:
Mycobacterium tuberculosis is a leading cause of human mortality worldwide, and the emergence of drug-resistant strains demands the discovery of new classes of antimycobacterial that can be employed in the therapeutic pipeline. Previously, a secondary metabolite, chrysomycin A, isolated from Streptomyces sp. OA161 displayed potent bactericidal activity against drug-resistant clinical isolates of M.
View Article and Find Full Text PDFKilling of persisters by a multitarget natural product chrysomycin A.
Sci Adv
August 2023
Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing 211166, China.
poses a severe public health problem as one of the vital causative agents of healthcare- and community-acquired infections. There is a globally urgent need for new drugs with a novel mode of action (MoA) to combat biofilms and persisters that tolerate antibiotic treatment. We demonstrate that a benzonaphthopyranone glycoside, chrysomycin A (ChryA), is a rapid bactericide that is highly active against persisters, robustly eradicates biofilms in vitro, and shows a sustainable killing efficacy in vivo.
View Article and Find Full Text PDFEnhanced Transdermal Peptide-Modified Flexible Liposomes for Efficient Percutaneous Delivery of Chrysomycin A to Treat Subcutaneous Melanoma and Intradermal MRSA Infection.
Adv Healthc Mater
October 2023
Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals & College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China.
Superficial skin diseases, including skin infections and tumors, are common healthcare burdens. In this study, the in vivo activity of chrysomycin A (CA) is explored, and a transdermal liposomal CA formulation is further constructed for the simultaneous treatment of cutaneous melanoma and cutaneous methicillin-resistant Staphylococcus aureus (MRSA) infection. The prepared liposomes (TD-LP-CA) display a strong antitumor effect with an IC value of less than 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!